A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Palbociclib
Related studies linked through entity extraction aliases.
G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations
- Status
- UNKNOWN
- Phase
- PHASE2
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Palbociclib and Cetuximab in Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Survival Prolongation by Rationale Innovative Genomics
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
HR+/HER2- Advanced Breast Cancer and Endocrine Resistance
- Status
- TERMINATED
- Phase
- PHASE2
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
- Status
- RECRUITING
- Phase
- PHASE2
Patterns of Prescribing and Monitoring of Palbociclib
- Status
- COMPLETED
- Phase
- N/A
Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.
- Status
- RECRUITING
- Phase
- PHASE2
Efficacy and Safety of Precision Therapy in Refractory Tumor
- Status
- UNKNOWN
- Phase
- PHASE2
Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Proton Pump Inhibitor (PPI, Rabeprazole) Effect On Tablet Formulation Of Palbociclib
- Status
- COMPLETED
- Phase
- PHASE1